A phase II clinical trial of poziotinib for non-small cell lung cancer with epidermal growth factor receptor exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.Â
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, researchers from MD Anderson Cancer Center found.Â
Results from a phase III COVID-19 study showed that oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, improved outcomes in hospitalized moderate-to-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death.
COVID-19 was the third leading cause of death in the United States between March 2020 and October 2021, according to an analysis of national death certificate data by researchers at NCI.Â
In a survey of nearly 1,200 recent cancer patients and survivors conducted as part of the American Cancer Society Cancer Action Network’s Survivor Views project, more than 80% of respondents said they would be willing to use remote technologies and tools in a trial.Â
Researchers at Cedars-Sinai Cancer and Johns Hopkins University discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice.
Cleveland Clinic researchers measured cellular interactions in a simplified tumor environment consisting of drug-resistant non-small cell lung cancer cells and drug-sensitive precursor cells, aiming to better understand how therapeutic resistance develops.
Results from the pivotal phase II MOUNTAINEER trial showed Tukysa (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer.Â
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute identified key features of a gene mutation responsible for 15-20% of all melanomas.
The SWOG Cancer Research Network has partnered with cloud clinical research software company nCoup to pilot and deploy the company’s nCartes platform at SWOG sites to help advance data collection.Â
